MedTrace Logo

The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function

NCT02473809 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-09-26

No results posted yet for this study

Summary

The purpose of this study is to test whether liraglutide, a drug approved and widely used in the treatment of type 2 diabetes, has an effect on bone mass and bone cell function. Type 2 diabetes may cause multiple complications, and it is well known that patients with type 2 diabetes have a higher risk of fractures. If Liraglutide can be demonstrated to have a positive effect on bone, this may be one among other factors to consider before the decision about specific treatment of type 2 diabetes is made for the individual patient.

Conditions

Interventions

DRUG

Liraglutide

Once daily

DRUG

Placebo

Once daily

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER

  • Novo Nordisk A/S

    collaborator INDUSTRY

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Bente L Langdahl, MD PhD DMSc · Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2017-10-31
Completion
2017-10-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02473809 on ClinicalTrials.gov